CERTIFICATE

IMPACT FACTOR 2021

Subject Area

  • Life Sciences / Biology
  • Architecture / Building Management
  • Asian Studies
  • Business & Management
  • Chemistry
  • Computer Science
  • Economics & Finance
  • Engineering / Acoustics
  • Environmental Science
  • Agricultural Sciences
  • Pharmaceutical Sciences
  • General Sciences
  • Materials Science
  • Mathematics
  • Medicine
  • Nanotechnology & Nanoscience
  • Nonlinear Science
  • Chaos & Dynamical Systems
  • Physics
  • Social Sciences & Humanities

Why Us? >>

  • Open Access
  • Peer Reviewed
  • Rapid Publication
  • Life time hosting
  • Free promotion service
  • Free indexing service
  • More citations
  • Search engine friendly

In silico analysis of the inhibitory activities of novel azo derivatives of benzimidazole on egfr (her-2) kinase domain

Author: 
Srilekha K., K. Krishnaveni, M. Kezia, Subhendu Nayak, Netala Silvia, Kotte Raju, Anuradha Khuntia, Geeta Mounika and Sujit Kumar Mohanty
Subject Area: 
Life Sciences
Abstract: 

Background: Epidermal growth factor receptors (EGFR) in human were involved in various types of cancers represented by abnormal signal transduction. This class consists of EGFR (ErbB1), HER2 (ErbB2, HER2), HER3 (ErbB3), and HER4 (ErbB4). Among them, EGFR and HER2 are related to breast cancer and are appropriate targets in dealing with various breast cancer cases. Disturbance of EGFR signalling, both by blocking EGFR binding sites or suppressing intracellular tyrosine kinase activity, can inhibit the rise of EGFR expressing tumours and recover the patient's condition. In this interest, a set of some new azo benzimidazole derivatives were prepared by coupling the diazonium derivative of benzimidazole with different suitable aromatic compounds and are used as ligands to dock against human HER2 kinase domain receptor. Materials and Methods: For this purpose, the crystal structure of the EGFR Kinase domain associated with TAK 285 (PDB ID: 3POZ, 1.5 Å X-ray resolution) was retrieved from the RCSB Protein Database (PDB) and used as the target. Results: All the compounds firmly inhibited by completely filling the active sites in the model with low energy values. Conclusion: Present study backed the in vitro activity of compounds designed by Mohanty et al., (4) and proved that the compounds of the current study inhibit the EGFR Kinase domain. So, these designed compounds can be used in drug development against some diseases that may somehow be related to the protein EGFR Kinase domain.

PDF file: 

CALL FOR PAPERS

 

ONLINE PAYPAL PAYMENT

IJMCE RECOMMENDATION

Advantages of IJCR

  • Rapid Publishing
  • Professional publishing practices
  • Indexing in leading database
  • High level of citation
  • High Qualitiy reader base
  • High level author suport

Plagiarism Detection

IJCR is following an instant policy on rejection those received papers with plagiarism rate of more than 20%. So, All of authors and contributors must check their papers before submission to making assurance of following our anti-plagiarism policies.

 

EDITORIAL BOARD

CHUDE NKIRU PATRICIA
Nigeria
Dr. Swamy KRM
India
Dr. Abdul Hannan A.M.S
Saudi Arabia.
Luai Farhan Zghair
Iraq
Hasan Ali Abed Al-Zu’bi
Jordanian
Fredrick OJIJA
Tanzanian
Firuza M. Tursunkhodjaeva
Uzbekistan
Faraz Ahmed Farooqi
Saudi Arabia
Eric Randy Reyes Politud
Philippines
Elsadig Gasoom FadelAlla Elbashir
Sudan
Eapen, Asha Sarah
United State
Dr.Arun Kumar A
India
Dr. Zafar Iqbal
Pakistan
Dr. SHAHERA S.PATEL
India
Dr. Ruchika Khanna
India
Dr. Recep TAS
Turkey
Dr. Rasha Ali Eldeeb
Egypt
Dr. Pralhad Kanhaiyalal Rahangdale
India
DR. PATRICK D. CERNA
Philippines
Dr. Nicolas Padilla- Raygoza
Mexico
Dr. Mustafa Y. G. Younis
Libiya
Dr. Muhammad shoaib Ahmedani
Saudi Arabia
DR. MUHAMMAD ISMAIL MOHMAND
United State
DR. MAHESH SHIVAJI CHAVAN
India
DR. M. ARUNA
India
Dr. Lim Gee Nee
Malaysia
Dr. Jatinder Pal Singh Chawla
India
DR. IRAM BOKHARI
Pakistan
Dr. FARHAT NAZ RAHMAN
Pakistan
Dr. Devendra kumar Gupta
India
Dr. ASHWANI KUMAR DUBEY
India
Dr. Ali Seidi
Iran
Dr. Achmad Choerudin
Indonesia
Dr Ashok Kumar Verma
India
Thi Mong Diep NGUYEN
France
Dr. Muhammad Akram
Pakistan
Dr. Imran Azad
Oman
Dr. Meenakshi Malik
India
Aseel Hadi Hamzah
Iraq
Anam Bhatti
Malaysia
Md. Amir Hossain
Bangladesh
Ahmet İPEKÇİ
Turkey
Mirzadi Gohari
Iran